Clinical Trial Update: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on tislelizumab combined with IMRT as neoadjuvant therapy for resectable hepatocellular carcinoma with portal vein tumor thrombus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Phase 2 | Status: UNKNOWN